Video

Addressing Fluctuating BCR-ABL Levels in CML

For High-Definition, Click

Fluctuations in BCR-ABL levels occurs frequently, and this often alarms patients, Neil Pravin Shah, MD, comments. To assess these fluctuations, Shah looks at the degree of change. All of the panelists consider a full log increase a cause for concern.

Shah and Stuart L. Goldberg, MD, agree that a dramatic increase in a patient’s BCR-ABL level may indicate a patient’s nonadherence to therapy. They state that a more gradual rise often indicates resistance. However, Shah states that if the level has jumped, he still feels obligated to check for a resistance mutation, since resistance could still be contributing to the change in BCR-ABL.

B. Douglas Smith, MD, states that if there is a rise in BCR-ABL levels, but not a full-log increase, he continues to use the 3-month monitoring schema. For a significant increase, which he defines as a log or greater, he recommends that the patient return for monitoring after 6 to 8 weeks instead of after 3 months.

Shah describes the worst case scenario as one in which a patient’s BCR-ABL level fluctuates between undetectable or weakly positive and being quantifiable. This scenario is challenging because it is usually not possible to determine how far below detectable the patient was, making it difficult to quantify the exact change.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity
Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina
Video

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Apr 17th 2025 - May 23rd 2025

online-activity
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Apr 17th 2025 - May 23rd 2025

online-activity